Health committee  Madam Chair, there is no jurisdiction that yet has the tool to deal with all the potential mixtures. We continue to assess individual substances. We can look at the cumulative exposures of that substance through all its potential uses, but when you look at mixtures in one product

Health committee  As the science evolves, with the general prohibition, we will be able to move, and move quickly.

Health committee  I have two comments. As other members have said, one of the concerns about establishing lists is that the science is constantly evolving. Our interest is not in maintaining the list but in dealing with unsafe products, so rather than coming back and adding to lists and having t

Health committee  There are two elements. First, we understand the reputation that CEPA had. The reputation that CEPA is developing is one of being much more nimble and much quicker. I would also return to the chemicals management plan. As a result of a parliamentary committee's direction to t

Health committee  We are looking at all the exposure pathways, with the onus on industry. It has rapidly accelerated the pace at which we are able to move through those substances. We will be through the top 500 priority substances very quickly, so CEPA is moving more quickly to do these assessmen

Health committee  Madam Chair, it is generally accepted and it is already in CEPA. This is a duplication of something that already exists.

Health committee  Has it led to full bans of products? No, we would acknowledge that. It did lead, for example, through the assessment of BPA, to the action taken to say that BPA does not belong in baby bottles and to the move to do that very quickly. There is an acknowledgement here that without

Health committee  Thank you, Madam Chair. With respect to the member's comments, I would respectfully suggest that Bill C-6 does create those incentives. It significantly changes the Hazardous Products Act. The penalties that we had were really not very significant, and the onus was on the govern

Health committee  We are not aware of any other jurisdictions that have gone quite this far with respect to this particular approach, that would be comparable in terms of the regulatory framework the Government of Canada would have to operate under.

Health committee  There are none that I am aware of at this time. We are aware of what is going on in California with respect to their approach to labelling. They have a very different regulatory regime. There is no enforcement; that aspect is left to the civil court. It's a completely different

Health committee  We acknowledge what California is doing; the enforcement is radically different.

Health committee  Thank you very much, Madam Chair, for the opportunity to comment on this amendment. The first point I would make is that this amendment would cause the department problems with respect to the scope of the amendment, as it differs quite significantly from what is in the original

Health committee  With respect to the member's comments, I will try to be as direct as possible. The general prohibition would allow us to move quickly to deal with that issue without creating the confusion, the overlap, and the duplication. We do agree and acknowledge that the science is consta

Health committee  I'm attempting to respond to all of the members' comments.

Health committee  The general prohibition is very broad and would allow us to move quickly, with respect to the previous commenter's comments. And the definition on page 3 does speak to...so chronic is covered in the act in terms of the definitions as it has been laid out. So again it comes back t